You are here

  • Home
  • Archive
  • Volume 11, Issue 4
  • Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, para…

Article metrics

Article menu
XML
Cardiovascular medicine
Protocol
Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study

 

Online download statistics by month:

Online download statistics by month: April 2021 to April 2024

AbstractFullPdf
Apr 202139236494
May 202113412754
Jun 202111811841
Jul 202114814523
Aug 2021727122
Sep 2021626318
Oct 2021313231
Nov 2021242326
Dec 2021272613
Jan 2022342816
Feb 2022272311
Mar 2022373921
Apr 2022929110
May 2022424124
Jun 2022302810
Jul 202211114
Aug 202218168
Sep 2022302820
Oct 2022212012
Nov 2022343015
Dec 202234305
Jan 2023313116
Feb 202320209
Mar 202341398
Apr 202312127
May 2023151311
Jun 2023232011
Jul 2023191914
Aug 2023322913
Sep 202327268
Oct 2023272516
Nov 202347427
Dec 2023313118
Jan 2024252512
Feb 2024303011
Mar 2024191914
Apr 202416138
Total18331748661